Lara Goldstein - Spark Newswire

2 minute read

Two Psychedelics Drug Development Companies Work To Produce Novel Plant-Based Compounds For Mental Health Disorders

Today, 6:29 PM

Filament Health Corp. (OTCQB: FLHLF) and Jaguar Health, Inc. (NASDAQ: JAGX) have signed a letter of intent for a collaboration agreement.

FLHLF

2 minute read

New Acquisition: Numinus To Buy Common Shares Of Novamind Pending Canadian Supreme Court Approval

By Lara Goldstein

Today, 6:29 PM

Numinus Wellness Inc.

NUMIF

1 minute read

Shrooms Move Forward For Palliative Care, Optimi To Supply High-Grade Psilocybin For Private Mental Health Practitioner In CA

By Lara Goldstein

Today, 6:29 PM

Optimi Health Corp.

OPTHF

2 minute read

New Share Consolidation of Lobe Sciences Ltd., Here’s What Changes

By Lara Goldstein

Today, 6:29 PM

Lobe Sciences Ltd.

LOBEF

1 minute read

Jefferies Global Healthcare Conference: Three Psychedelic Biotech Companies To Participate This Week

By Lara Goldstein

Today, 6:29 PM

The 2022 Jefferies Global Healthcare Conference is an annual gathering where over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs address near-term and long-term investment opportunities and discuss current trends driving healthcare in the U.S. and internationally.

DMTTF

2 minute read

Addiction Relapse Prevention: Nirvana Pre-Clinical Study Suggests Psilocybin Could Help Heroin Addiction

By Lara Goldstein

Today, 6:29 PM

Nirvana Life Sciences Inc. (CSE: NIRV) is a Canadian-based life sciences company that develops novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction treatment and ongoing pain management. Nirvana has recently joined forces with Integrative Therapy Discovery (ITD) Labs of Italy.

CSE:NIRV

2 minute read

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

By Lara Goldstein

Today, 6:29 PM

Ehave, Inc. (OTC Pink: EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health.

EHVVF

1 minute read

Patent For Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine

By Lara Goldstein

Today, 6:29 PM

India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF).

CMNDF

2 minute read

Major Depressive Disorder Could Soon Have Treatment Option Via Cybin’s Psilocybin Analog

By Lara Goldstein

Today, 6:29 PM

Cybin Inc. (CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics," has submitted an Investigational New Drug (or “IND”) application to the FDA.

CYBN

2 minute read

Silo Wellness To Acquire Canadian Dyscovry Science, Producer Of Psilocybin For IBS Treatment

By Lara Goldstein

Today, 6:29 PM

Silo Wellness (SILFF), a growth-oriented holding company focused on functional mushroom and psychedelic opportunities, has presented a nonbinding letter of intent to fully acquire Dyscovry Science Ltd.

SILFF